About Respiratory Syncytial Virus (RSV) Fusion Glycoprotein F0 Recombinant Protein

Respiratory Syncytial Virus (RSV) is an enveloped, negative-sense single-stranded RNA virus belonging to the genus Orthopneumovirus in the family Pneumoviridae. The Fusion glycoprotein F0 is the inactive precursor of the RSV F protein and is proteolytically cleaved into the F1 and F2 subunits to generate the mature fusion protein required for viral entry. The F protein mediates fusion of the viral envelope with the host cell membrane and is the primary target of neutralizing antibodies and current RSV vaccines. Because of its essential role in infection and its highly conserved sequence, RSV F0 is widely used in studies of viral entry, antibody discovery, and vaccine development.

eEnzyme's RSV Fusion Glycoprotein F0 Recombinant Protein is produced for research use and is suitable for antibody screening, ELISA development, Western blotting, epitope mapping, structural characterization, and RSV vaccine research. This recombinant protein provides a valuable reagent for investigating RSV fusion mechanisms, host immune responses, and antiviral therapeutic development.

Applications

Biological Significance of RSV Fusion Glycoprotein F0

RSV F0 is the precursor of the mature fusion protein that undergoes proteolytic cleavage to produce the biologically active F1-F2 complex responsible for membrane fusion and viral entry. The mature F protein exists in prefusion and postfusion conformations, with the prefusion form containing the most potent neutralizing epitopes recognized by protective antibodies. Consequently, RSV F0 and its processed forms remain central to studies of RSV pathogenesis, vaccine design, therapeutic antibody development, and antiviral drug discovery.